Key Highlights

  • Shares dropped roughly 20% on November 9, 2026, reaching about USD 6.89 against a USD 8.64 close the prior Friday, and trading Volume ran at more than double its typical pace.
  • Anktiva's third-quarter net product sales climbed 53% to USD 48.7 million, yet total Revenue around USD 48.8 million came in under forecasts near USD 59.2 million.
  • The period broke a streak of eight straight quarters of sequential expansion and landed beneath the USD 50.7 million peak set in the second quarter.
  • The net loss grew to USD 184.6 million after a USD 77.9 million non-cash charge linked to Fair Value shifts in a related-party convertible note and warrants, and cash and investments totaled USD 334.3 million.

Momentum Unwinding Rather Than a Growth Miss

The drop in ImmunityBio (NASDAQ:IBRX) reflected direction more than growth itself. Compared with a year earlier, sales were strong, yet investors had priced in another sequential step up following a long streak of gains and a share price that had climbed around 300% across the previous twelve months. Quarterly sales slipped from USD 50.7 million to USD 48.7 million when forecasts had pointed to a climb toward USD 59 million, which hinted that Anktiva's commercial ramp in bladder cancer could be lumpy. Momentum-oriented holders sold swiftly, and the scale of the move mirrored how far expectations had outrun reported results. The headline loss was also far larger than a year earlier, though most of the widening stemmed from a non-cash accounting entry linked to the elevated share price, not day-to-day operating outlays. Research and Development outlays reached USD 71.5 million, while selling, general and administrative spending hit USD 54.0 million as the company builds out its commercial footprint.

Trial Progress, Approvals and Long-Term Survival Data

The quarter carried notable clinical and regulatory developments. Within the QUILT-2.005 trial, Cohort A, which enrolled 370 people who were BCG-naive, each with high-grade non-muscle invasive bladder cancer, reached its primary goal for Anktiva combined with BCG relative to BCG alone, and the firm intends to submit a supplemental application during the fourth quarter of 2026. The FDA broadened the label in October to include more patients unresponsive to BCG, including those with high-grade papillary-only growths. Anktiva also received approval in Israel via a regional partner, and the first European patients were dosed on November 4. Long-term figures released in October indicated that 84% of patients were spared bladder removal at 36 months. Nine-month product sales of USD 143.6 million already exceed the USD 113.0 million booked during all of 2025. Leadership noted that a growing number of physicians are writing prescriptions for several patients, a sign that clinicians are growing comfortable with the treatment.

Lumpy Quarters, Cash Runway and the Next Filing

Choppy quarterly sales remain the principal hazard as Anktiva reaches a wider audience, and that could keep the shares volatile. ImmunityBio (NASDAQ:IBRX) still posts heavy losses, and although USD 334.3 million in cash and investments offers a buffer, more Capital raising is not off the table if costs keep climbing. BCG supply, which pairs with Anktiva, has been constrained previously and might limit expansion. Market Participants should monitor fourth-quarter product sales for a resumption of sequential growth, the timing and result of the planned submission built on the BCG-naive data, the rollout pace in Europe and elsewhere and how the convertible note and Warrant liabilities move.

Where Things Stand

Shares of ImmunityBio (NASDAQ:IBRX) dropped roughly 20% on November 9, 2026, after third-quarter Anktiva sales came in at USD 48.7 million, up 53% year over year but lower than the prior quarter and short of forecasts. Clinical and regulatory progress was solid, featuring a positive Phase 3 cohort and fresh clearances. Sales in the coming quarter will show whether the decline overshot.